Einarson T R, Bootman J L, Smith G H
Drug Intell Clin Pharm. 1984 Jul-Aug;18(7-8):560-8. doi: 10.1177/106002808401800702.
Chymopapain is a proteolytic enzyme injected intradiscally for the treatment of herniated lumbar discs. The average success rate is 73 percent for elimination of backache and sciatica. Side effects occur in three percent of patients, the most serious being anaphylaxis in about one percent. A majority of patients experience severe back pain or spasms during the first 24-48 hours after treatment. This treatment modality consumes fewer hospital days and produces a quicker return to work than does surgery. It does not affect subsequent surgical procedures adversely. Chymopapain chemonucleolysis is safe and effective when administered by experienced physicians and when adequate precautions are taken. It can be considered the last step before surgery in the conservative management of herniated lumbar discs.
木瓜凝乳蛋白酶是一种经椎间盘内注射用于治疗腰椎间盘突出症的蛋白水解酶。消除背痛和坐骨神经痛的平均成功率为73%。3%的患者会出现副作用，最严重的是约1%的患者会发生过敏反应。大多数患者在治疗后的最初24至48小时内会经历严重的背痛或痉挛。与手术相比，这种治疗方式住院天数更少，能更快恢复工作。它不会对后续手术造成不利影响。当由经验丰富的医生操作并采取适当预防措施时，木瓜凝乳蛋白酶化学髓核溶解术是安全有效的。在腰椎间盘突出症的保守治疗中，它可被视为手术前的最后一步。
